Calaspargase pegol-mknl


Calaspargase pegol-mknl

Drug updated on 11/16/2023

Dosage FormInjection (intravenous; 3,750 units/5 mL)
Drug ClassAsparagine specific enzymes
Ongoing and
Completed Studies


  • Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients aged 1 month to 21 years.

Product Monograph / Prescribing Information

Document TitleYearSource
Asparlas (calaspargase pegol-mknl) Prescribing Information.2022Servier Pharmaceuticals LLC., Boston, MA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy. 2022Blood and Lymphatic Cancer: Targets and Therapy

Clinical Practice Guidelines

Document TitleYearSource
Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit. 2021Current Hematologic Malignancy Reports
Pediatric acute lymphoblastic leukemia, version 2.2020.2020NCCN Clinical Practice Guidelines in Oncology